お知らせ • Jan 15
GlobeStar Therapeutics Corporation Files Form 15 GlobeStar Therapeutics Corporation has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common stock under the Securities Exchange Act of 1934, as amended. お知らせ • Aug 15
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 08/14/2024, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 18
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 05/17/2024, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Feb 16
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 02/15/2024, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Nov 03
GlobeStar Therapeutics Enters into Definitive Agreement with Advanced Innovative Partners to Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment GlobeStar Therapeutics Corporation announced that building on its recent agreement with SMI HealthCare LLC (SMIHC) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East. GlobeStar has also entered into a definitive agreement with Advanced Innovative Partners (AIP) for AIP to provide advice to GlobeStar and SMIHC on the global design, strategy and execution of clinical trials, regulatory filing, intellectual property rights filings, and manufacturing for Project Amethyst™?. Project Amethyst™? is a compound intended to treat neurodegeneration from multiple sclerosis (MS). GSTC is the exclusive worldwide licensee for Project Amethyst™?, including all patents and patent applications relatingo. The GlobeStar and AIP agreement has been approved by the parties' respective boards and is immediately effective. AIP will initially advise Globe Star and SMIHC on the design and launch of an initial clinical trial in India and the associated regulatory approvals for GSTC's MS products in North America and Europe. According to the U.S. National Institutes of Health, between 2013 and 2020, the reported incidence of MS has increased by approximately 50% in the 81 most affected countries. Pursuant to the parties' agreement, GlobeStar retains ownership of all intellectual property rights, and final approval of Project Am Amethyst™?, including the right to engage additional advisors and subject matter experts. For its consulting services, AIP will be paid a monthly consulting fee and bonuses, a portion of which will be deferred and will become payable only if GlobeStar secures FDA marketing approval. If AIP introduces GlobeStar or SMIHC to potential customers, or strategic partners, subject to compliance with applicable law, AIP may also become entitled to receive commissions on certain revenues or profits derived from those relationships. GlobeStar was advised by an affiliate of SMI Group LLC in this transaction. お知らせ • May 16
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 05/15/2023, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Dec 30
GlobeStar Therapeutics Corporation announced delayed annual 10-K filing On 12/29/2022, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Aug 16
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 08/15/2022, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 17
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 05/16/2022, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Dec 31
GlobeStar Therapeutics Corporation announced delayed annual 10-K filing On 12/30/2021, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Aug 17
GlobeStar Therapeutics Corporation announced delayed 10-Q filing On 08/16/2021, GlobeStar Therapeutics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 18
AngioSoma, Inc. announced delayed 10-Q filing On 05/17/2021, AngioSoma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Mar 07
AngioSoma, Inc. Announces Executive Changes On March 3, 2021, the Board of Directors of AngioSoma, Inc. appointed James C. Katzaroff Director, President and Chief Executive Officer of the corporation. On March 3, 2021, the Board of Directors of the Company accepted Alex K. Blankenship’s resignation from all positions with the Company. Ms. Blankenship also transferred voting control to James C. Katzaroff. James C. Katzaroff successfully negotiated with the holder of a patented treatment for Multiple Sclerosis for an exclusive perpetual license. Mr. Katzaroff is the founder of Advanced Medical Isotope Corp. (now known as Radiogel) and was the Chairman and Chief Executive Officer from 2007 through December 2016. Since December 2016 to present, Mr. Katzaroff is Senior Managing Director at KATMO, LLC.